Public Market Listing
Live quotes, historical charts, and market capitalization for Sino Biopharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(16 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary Disease | |
| Phase 3 | CDK2/CDK4/CDK6 · CDK2/4/6/CDK4Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
Garsorasib(Anfangning) | Phase 3 | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer |
| Phase 3 | AKT (inhibitor)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | HBV core protein | Chronic Hepatitis B | |
| Phase 3 | BCMA x CD3Multispecific antibody | Multiple Myeloma | |
| Phase 3 | PDE3/PDE4Small molecule | Chronic Obstructive Pulmonary Disease | |
| Phase 3 | TYK2Small molecule | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisSystemic Lupus Erythematosus Ulcerative Colitis, Crohn's Disease | |
| Phase 2 | Lipoprotein(a)RNA / oligonucleotide | Atherosclerotic Cardiovascular Disease | |
| Phase 2 | TLR8 | Chronic Hepatitis B | |
| Phase 2 | IL-36 receptor (IL-36R)Monoclonal antibody | Psoriasis | |
| Phase 1/2 | — | Chronic Hepatitis B | |
| Phase 1 | APOC3RNA / oligonucleotide | Cardiovascular Disease / Dyslipidemia Hypertriglyceridemia | |
| Phase 1 | GPRC5D x CD3Multispecific antibody | Multiple Myeloma | |
TQB3602No recent activity | Phase 1 | ProteasomeSmall molecule | Multiple Myeloma |
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (6)
February 2027 (1)
March 2027 (1)
August 2027 (1)
September 2027 (1)
November 2027 (1)
December 2027 (1)
What to watch
2028 (3)
August 2028 (1)
September 2028 (1)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (5)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $2.4B | $440M | $1.5B | — | report ↗ |
Sino Biopharmaceutical reported revenue of $2,424.38M, up 9.9% YoY, with R&D spend of $439.83M, up 22.7% YoY. Cash and equivalents were $1,549.61M. Profit attributable to owners of the parent from continuing operations was approximately RMB3.39 billion, up 140.2% YoY, with earnings per share of approximately RMB18.82 cents; underlying profit attributable to owners was approximately RMB3.09 billion, up 101.1% YoY.
During 1H 2025, two innovative products were approved by the NMPA (Putanning and Anqixin), and five generic drugs received approval; innovative product sales reached RMB7.8 billion, up 27.2% YoY. The company reported 37 innovative oncology candidates, 7 liver/metabolic candidates, 13 respiratory candidates, and 6 surgery/analgesia candidates in clinical trial application or above, including multiple Phase III programs such as Lanifibranor for MASH. In July 2025, the company announced the full acquisition of LaNova Medicines, and the board recommended an interim dividend of HK5 cents per share.
View 4 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-H1 | $2.2B | $358M | $1.2B | — | report ↗ |
| 2023-H1 | $2.2B | $340M | $1.6B | — | report ↗ |
| 2022-H1 | $2.3B | $317M | $1.2B | — | report ↗ |
| 2021-H1 | $2.2B | $275M | $1.2B | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $4.7B | $866M | $1.8B | — | report ↗ |